TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to study the efavirenz-rifabutin interaction. Thus, this trial will
enroll patients with HIV and tuberculosis co-infections who are receiving a rifabutin-based
regimen and who plan to begin an antiretroviral regimen containing efavirenz dosed at 600 mg
daily. Enrollment in TB Trials Consortium Study 23 is not a requirement for participation in
this study.
Primary Objective:
To compare the pharmacokinetics of rifabutin at 600 mg twice a week in combination with
efavirenz 600 mg daily to the pharmacokinetics of rifabutin 300 mg twice a week without
efavirenz.
Phase:
Phase 2
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development